QHSLab, Inc.
Key statistics
from XBRL data in SEC filingsAI briefing
from the latest 10-K, 10-Q and 8-K eventsQHSLab, Inc. is a digital health company providing workflow-integrated behavioral health screening and follow-up care management to independent primary care practices, with an additional allergy diagnostics and treatment service line.
What they do
QHSLab offers a digital platform that enables primary care practices to screen, document, and manage behavioral health conditions (behavioral vital signs) through assessments administered before or outside office visits, adaptive logic, automated reports, EHR delivery, and ongoing digital follow-up. The platform generates recurring per-patient, per-month fees paid by practices. The AllergiEnd service line provides allergy diagnostics and treatment within primary care settings, operating in coordination with the digital platform.
Revenue drivers
- QHSLab digital platform subscriptions — Recurring per-patient, per-month fees paid by medical practices for platform access, digital care workflows, and support services; primary revenue source.
- AllergiEnd allergy diagnostics and treatment — Allergy diagnostics and treatment service line designed for primary care practices; operates alongside the digital platform.
Recent performance
Revenue for Q2 2026 (three months ended June 30, 2026) was $847,490, up from $605,446 in Q2 2025. Six-month 2026 revenue was $1,576,175 versus $1,250,865 in the prior-year period. Annual revenue grew from $2.1M in 2024 to $2.7M in 2025, though net income swung from a loss of $259,239 in 2024 to a profit of $457,417 in 2025, partly due to a ~$666,000 debt extinguishment gain. Recent quarterly revenue has trended upward from $737,066 in Q3 2025 to $847,490 in Q2 2026. The company had $317,392 in cash as of June 30, 2026.
Strategy
QHSLab focuses on expanding its digital platform across independent primary care practices as an extension of existing clinical workflows. Management emphasizes the platform's modular design to add new clinical domains and assessment variables. The AllergiEnd service line is intended to operate synergistically with the digital platform to identify and manage allergic disease in primary care. The company is pursuing reimbursable non-face-to-face and care management workflows enabled by the platform.
Risks
- Going concern uncertainty — The independent auditor's report on 2025 financials raised substantial doubt about the company's ability to continue as a going concern.
- History of losses and thin revenue base — Net losses were recorded in 2024 and prior years; revenues were only $2.7M in 2025, and profitability was partly due to debt extinguishment gain.
- Dependence on external financing — Operations have been supported by loans ($362,168 in 2025 and 2024) and equity issuance ($499,998); future growth may require additional debt or equity.
- Liquidity constraints — Cash and equivalents fell from $636,157 at end of 2025 to $317,392 at June 30, 2026, while current liabilities included $95,548 due to related party.
Outlook
Management's forward-looking statements indicate expectations for continued revenue growth and expanded platform adoption, but actual results may differ materially due to uncertainties. There is no assurance the company will sustain profitability or avoid additional financing needs. The company continues to prioritize adding new clinical domains and practice enrollments.